1
|
Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem 2020; 15:1862-1874. [PMID: 32743945 DOI: 10.1002/cmdc.202000419] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Indexed: 12/25/2022]
Abstract
Passive permeability is a key property in drug disposition and delivery. It is critical for gastrointestinal absorption, brain penetration, renal reabsorption, defining clearance mechanisms and drug-drug interactions. Passive diffusion rate is translatable across tissues and animal species, while the extent of absorption is dependent on drug properties, as well as in vivo physiology/pathophysiology. Design principles have been developed to guide medicinal chemistry to enhance absorption, which combine the balance of aqueous solubility, permeability and the sometimes unfavorable compound characteristic demanded by the target. Permeability assays have been implemented that enable rapid development of structure-permeability relationships for absorption improvement. Future advances in assay development to reduce nonspecific binding and improve mass balance will enable more accurately measurement of passive permeability. Design principles that integrate potency, selectivity, passive permeability and other ADMET properties facilitate rapid advancement of successful drug candidates to patients.
Collapse
Affiliation(s)
- Li Di
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, CT 06340, USA
| | - Per Artursson
- Department of Pharmacy, Uppsala University, 752 36, Uppsala, Sweden
| | - Alex Avdeef
- in-ADME Research, 1732 First Avenue, #102, New York, NY 10128, USA
| | - Leslie Z Benet
- Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA 94143, USA
| | - J Brian Houston
- Division of Pharmacy & Optometry, Stopford Building, Oxford Road, Manchester, M13 9PT, UK
| | | | | | - Hans Lennernäs
- Department of Pharmacy, Uppsala University, 752 36, Uppsala, Sweden
| | | | - Kiyohiko Sugano
- College of Pharmaceutical Sciences, Department of Pharmacy, Ritsumeikan University, Noji-higashi, Kusatsu, Shiga, 525-8577, Japan
| |
Collapse
|
2
|
Beyeh NK, Pan F, Valkonen A, Rissanen K. Encapsulation of secondary and tertiary ammonium salts by resorcinarenes and pyrogallarenes: the effect of size and charge concentration. CrystEngComm 2015. [DOI: 10.1039/c4ce01927j] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Multiple weak interactions are manifested in the complexation of different categories of secondary and tertiary alkyl ammonium salts with resorcinarenes and pyrogallarene leading to open inclusion and dimeric capsular assemblies with varying binding affinities, and analyzed in solid, liquid and gas phases.
Collapse
Affiliation(s)
- N. K. Beyeh
- Department of Chemistry
- Nanoscience Center
- University of Jyväskylä
- , Finland
| | - F. Pan
- Department of Chemistry
- Nanoscience Center
- University of Jyväskylä
- , Finland
| | - A. Valkonen
- Department of Chemistry
- Nanoscience Center
- University of Jyväskylä
- , Finland
- Department of Chemistry and Bioengineering
| | - K. Rissanen
- Department of Chemistry
- Nanoscience Center
- University of Jyväskylä
- , Finland
| |
Collapse
|
3
|
Clas SD, Sanchez RI, Nofsinger R. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. Drug Discov Today 2014; 19:79-87. [DOI: 10.1016/j.drudis.2013.08.014] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2013] [Revised: 07/31/2013] [Accepted: 08/19/2013] [Indexed: 01/01/2023]
|
4
|
de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL. ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol 2012; 8:1247-61. [PMID: 22808933 DOI: 10.1517/17425255.2012.708023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Restless legs syndrome (RLS) is a common neurological disorder that might impair nocturnal rest causing decreased alertness, depressed mood, reduced job performance, and poor quality of life. In patients affected by severe RLS, a pharmacological treatment is mandatory. AREAS COVERED The present review is based on a search using PubMed from 1994 to 2012. It is focused on the Absorption, Distribution, Metabolism, Elimination and Toxicology (ADMET) characteristics of the most used medications for RLS. In particular, the ADMET characteristics of dopaminergic agents, anticonvulsants able to improve neuropathic pain, and iron were discussed. EXPERT OPINION Clinical trials have showed that non-ergolic dopamine agonists are efficacious and safe for patients affected by moderate to severe idiopathic RLS. However, no head-to-head study has compared the long-term effects of the three dopamine agonists approved by the FDA for RLS (ropinirole, pramipexole, and rotigotine). Moreover, further studies should investigate the extended-release formulation of ropinirole and pramipexole in RLS patients affected by all day long distressing symptoms. A standardized treatment for symptomatic forms of RLS is lacking. Randomized, placebo-controlled trials should be performed at least in RLS patients with peripheral neuropathic and chronic kidney disease. Concerning RLS due to iron deficiency, a head-to-head study comparing efficacy, safety and compliance of oral iron versus intravenous one seems to be needed.
Collapse
Affiliation(s)
- Stefano de Biase
- Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy
| | | | | | | | | |
Collapse
|
5
|
Manconi M, Ferri R, Zucconi M, Bassetti CL, Fulda S, Aricò D, Ferini-Strambi L. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012; 71:834-44. [DOI: 10.1002/ana.23565] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
6
|
Rahimdel AG, Ayatollahi P, Zeinali A, Mehrabanian N, Mellat-Ardekani A. The effect of selenium administration on restless leg syndrome treatment. IRANIAN RED CRESCENT MEDICAL JOURNAL 2012; 14:14-9. [PMID: 22737548 PMCID: PMC3372025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/22/2011] [Accepted: 09/14/2011] [Indexed: 10/25/2022]
Abstract
BACKGROUND Restless leg syndrome (RLS) is defined as an uncomfortable feeling in the limbs which is prominently sensed in legs. Dopamine system involvement is considered as the base of RLS's etiology. Because of safety, anti-oxidant and dopaminergic promoting action of selenium, this study aims to investigate the effect of selenium on restless leg syndrome treatment. METHODS Sixty patients with primary RLS were enrolled in this clinical trial (Irct2011103015943n1). It was based on 3 periods of drug prescription with one month wash out period. As placebo, 50 and 200 μg of selenium were administered in each separated month. The diagnosis was based on criteria published by IRLSG (International RLS Study Group). The questionnaire included 10 questions while each question's rating was between 0 and 4. Points between 1 and 10 were considered mild, 11 to 20 as moderate, 21 to 30 as severe and 31 to 40 as very severe. After end of each month of drug consumption, questionnaires were completed and each subject was asked to report the severity of disease and side effects of the drugs. At least 10 declines in scale were considered as appropriate responses. RESULTS Improvement (decline IRLS score >10) was significantly higher in selenium (50 and 200 μg) than placebo group. CONCLUSION Selenium prescription in daily recommended dose of 50 μg instead of a dopamine agonist would be an alternative treatment in improvement of RLS symptoms.
Collapse
Affiliation(s)
- A G Rahimdel
- Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran
| | - P Ayatollahi
- Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran
| | - A Zeinali
- Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran
| | - N Mehrabanian
- Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran
| | - A Mellat-Ardekani
- Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran,Correspondence: Ali Mellat-Ardekani, MD, Assistant Professor of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran. Tel.: +98-351-8224001, E-mail:
| |
Collapse
|
7
|
Werremeyer AB. New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon. Ment Health Clin 2011. [DOI: 10.9740/mhc.n89391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Gabapentin enacarbil was approved by the Food and Drug Administration (FDA) in April of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.
Collapse
Affiliation(s)
- Amy B. Werremeyer
- Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, Nursing and Allied Sciences, North Dakota State University
| |
Collapse
|
8
|
Fowler DA, Tian J, Barnes C, Teat SJ, Atwood JL. Cocrystallization of C-butyl pyrogallol[4]arene and C-propan-3-ol pyrogallol[4]arene with gabapentin. CrystEngComm 2011. [DOI: 10.1039/c0ce00661k] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
9
|
Thorpe AJ, Clair A, Hochman S, Clemens S. Possible Sites of Therapeutic Action in Restless Legs Syndrome: Focus on Dopamine and α 2δ Ligands. Eur Neurol 2011; 66:18-29. [DOI: 10.1159/000328431] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Accepted: 04/11/2011] [Indexed: 01/01/2023]
|
10
|
Jones R, Rickards H, Cavanna AE. Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome. J Cent Nerv Syst Dis 2010; 2:45-55. [PMID: 23861631 PMCID: PMC3661230 DOI: 10.4137/jcnsd.s4886] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Restless Legs Syndrome (RLS) is a prevalent sleep-associated movement disorder greatly affecting patients’ quality of life (QoL). Several drugs can be used to control this condition although the first-line dopamine agents often cause adverse effects. Non-dopaminergic drugs such as oral gabapentin (GBP) have been more recently advocated. Despite ameliorating RLS symptoms, GBP’s pharmacokinetic limitations restrict its overall effectiveness. A novel specifically designed prodrug, gabapentin enacarbil (GE), has demonstrated successful RLS alleviation with a superior pharmacokinetic profile. This review aims to examine the efficacy and tolerability of both GBP and GE as pharmacotherapy for RLS. Despite some heterogeneity and limitations across research methodologies, GE appears to be a potential RLS therapy superior to GBP and other dopaminergic agents.
Collapse
Affiliation(s)
- Ruth Jones
- Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK
| | - Hugh Rickards
- Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK
| | - Andrea Eugenio Cavanna
- Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK
- Department of Neurology, UHB and University of Birmingham, Birmingham, UK
- Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, UK
| |
Collapse
|